LON:STX Shield Therapeutics (STX) Share Price, News & Analysis GBX 2.44 -0.01 (-0.37%) As of 11:20 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesBuy This Stock About Shield Therapeutics Stock (LON:STX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Shield Therapeutics alerts:Sign Up Key Stats Today's Range 2.43▼ 2.4850-Day Range 2.26▼ 3.2052-Week Range 1.50▼ 5.87Volume504,393 shsAverage Volume2.34 million shsMarket Capitalization£24.09 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewShield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S. with an exclusive, multi-year commercial agreement with Viatris Inc. (Viatris). Outside of the U.S., the Company has licensed the rights to four specialty pharmaceutical companies. Feraccru® is commercialized in the UK and European Union by Norgine B.V. (Norgine), which also has marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialization of Accrufer®/ Feraccru® in China, Hong Kong, Macau and Taiwan; with Korea Pharma Co., Ltd. for the Republic of Korea (Korea Pharma); and with KYE Pharmaceuticals Inc. for Canada. Accrufer®/Feraccru® has patent coverage until the mid-2030s. Accrufer®/Feraccru® are registered trademarks of Shield Therapeutics.Read More… Receive STX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Shield Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address STX Stock News HeadlinesShield Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues LagApril 26, 2025 | uk.finance.yahoo.comShield Therapeutics secures ACCRUFeR® deal in JapanApril 23, 2025 | investing.comAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new invention… This could send many popular AI stocks crashing, including Nvidia. And it could happen starting as soon as June 1st.May 22, 2025 | Paradigm Press (Ad)Shield Therapeutics Launches ACCRUFeR® in Canada to Address Iron Deficiency AnemiaMarch 11, 2025 | tipranks.comShield Therapeutics CEO Buys 575,000 Company SharesFebruary 13, 2025 | msn.comShield Therapeutics awards CEO share optionsFebruary 13, 2025 | msn.comShield Thera Regulatory NewsFebruary 9, 2025 | lse.co.ukTyneside pharma firm Shield Therapeutics appoints new US-based CEOJanuary 28, 2025 | msn.comSee More Headlines STX Stock Analysis - Frequently Asked Questions How have STX shares performed this year? Shield Therapeutics' stock was trading at GBX 2.70 at the beginning of 2025. Since then, STX stock has decreased by 9.6% and is now trading at GBX 2.44. View the best growth stocks for 2025 here. How were Shield Therapeutics' earnings last quarter? Shield Therapeutics plc (LON:STX) issued its earnings results on Thursday, April, 24th. The company reported ($3.00) EPS for the quarter. Shield Therapeutics had a negative net margin of 173.43% and a negative trailing twelve-month return on equity of 470.50%. How do I buy shares of Shield Therapeutics? Shares of STX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Shield Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Shield Therapeutics investors own include AcelRx Pharmaceuticals (ACRX), Rockwell Medical (RMTI), AstraZeneca (AZN), Model N (MODN), Cara Therapeutics (CARA), Caladrius Biosciences (CLBS) and Cellectis (CLLS). Company Calendar Last Earnings4/24/2025Today5/22/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryComputer Hardware Current SymbolLON:STX CIKN/A Webwww.shieldtherapeutics.com Phone+44-191-5118500FaxN/AEmployees40,000Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (3.88) Trailing P/E RatioN/A Forward P/E Ratio35.33 P/E GrowthN/ANet Income£-36,277,039.98 Net Margins-173.43% Pretax MarginN/A Return on Equity-470.50% Return on Assets-47.85% Debt Debt-to-Equity Ratio3,691.50 Current Ratio1.05 Quick Ratio2.16 Sales & Book Value Annual Sales£20.92 million Price / Sales1.18 Cash FlowGBX 0.39 per share Price / Cash Flow6.36 Book ValueGBX 0.05 per share Price / Book45.68Miscellaneous Outstanding Shares986,864,211Free FloatN/AMarket Cap£24.67 million OptionableNot Optionable Beta1.42 A Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free Report This page (LON:STX) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredThe Collapse Has Already Started — Your 401(k) Is NextThere's a major heist happening on American wealth in real time. Except this one doesn't involve masks or v...American Hartford Gold | SponsoredElon’s 2025 Silver Crisis (What It Means for You)Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless p...GoldenCrest Metals | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredThe DOJ Just Said Your Money Isn’t YoursWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Shield Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Shield Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.